3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Sarcoma
2
Thoracic
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Melanoma
2
Kidney Neoplasms
2
Head and Neck Neoplasms
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Thymus Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Kaposi
1
Sarcoma
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pheochromocytoma
1
Pharyngeal Neoplasms
1
Penile Neoplasms
1
Parotid Neoplasms
1
Parathyroid Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Interventions
Cyclophosphamide
6
pembrolizumab
3
Filgrastim
3
fludarabine
2
Nivolumab
2
Mesna
2
Ipilimumab
2
Ifosfamide
2
Gemcitabine
2
Etoposide
2
Docetaxel
2
Cryosurgery
2
Carboplatin
2
tocilizumab
1
tipifarnib
1
tanespimycin
1
poly ICLC
1
montanide ISA 51
1
lorukafusp alfa
1
humanized 3F8 anti-GD2 monoclonal antibody
1
fludarabine phosphate
1
flt3 ligand protein
1
entinostat
1
dostarlimab
1
cc-486
1
X-Rays
1
Thrombopoietin
1
Therapeutics
1
Thalidomide
1
Specimen Handling
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Osteosarcoma
×
Patient Reported Outcome Measures
×
Dermatologic
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled